PepGNP-Dengue

Developed for: dengue disease
Investigated by: Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland · Gylden Pharma Ltd · University of Lausanne Hospitals

today NCT04935801 · Ph 1

20222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT04935801	Aug 2021 → Mar 2022	dengue disease	Gylden Pharma Ltd	Completed	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	PepGNP-Dengue	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04935801 ↗